Hypertension drug does not increase breast cancer risk for women over 55

(Medical Xpress) -- A commonly prescribed medicine used to treat conditions such as heart failure and hypertension does not present women over 55 with any increased risk of breast cancer, a new study at the University of Dundee has shown.

Many breast cancers are (oestrogen) dependent. The medicine, , blocks () and increases the relative effects of . As such, spironolactone can cause painful breast enlargement by altering the balance of male to female hormonal effects allowing the female effects to predominate.

This led to fears that this mechanism might increase hormone-dependent breast cancer in women, something researchers in the School of Medicine at Dundee has disproved in the case of women over the age of 55. They looked at data held in the General Practice Research Database (GPDR) relating to women over the age of 55 who had no history of breast cancer.

By examining anonymized medical records they were able to compare how many of the 28,000 women who had received spironolactone treatment went on to develop breast cancer with 56,000 women who had not been administered the drug. They found no association between exposure to spironolactone and the risk of breast cancer.

Use of spironolactone has increased greatly in recent years and is expected to rise further following changes in guidelines on hypertension treatment from the National Institute for Health and Clinical Excellence (NICE).

"Recent UK blood pressure guidelines recommend the use of spironolactone for patients with difficult-to-treat hypertension, meaning increasing numbers of people are being treated with it," explained Dr. Isla Mackenzie, Clinical Senior Lecturer and Honorary Consultant in at the University.

"This is a drug that has hormonal effects and can lead to swelling in the breasts as a side effect, and so this is why it was important to determine whether or not it led to an increased risk of breast cancer. What our study showed is that, in women over 55, there was no increased risk at all for women who have been treated with spironolactone.

"By looking at a large number of patients we were able to determine that there was no for women in this age group. This is important because the drug has become much more commonly used in recent years, and is now being given to a lot of women.

"With the numbers of women in this group receiving spironolactone set to increase further, it was important to obtain reassurance that the risk of breast cancer was not raised, which our research has indeed shown."

Breast cancer is the most common cancer in women in the UK. About 46,000 women get breast cancer in the UK each year. Most of them (8 out of 10) are over 50, but younger , and in rare cases men, can also get .

The research, which appears in the latest edition of the British Medical Journal, was carried out through examining anonymised data from the GPRD.

The GPRD, managed by the Secretary of State for Health, United Kingdom (UK) contains over 3 million active patient records drawn from approximately 400 primary care practices in the UK. The Medicine Control Agency manages the GRPD. The GPRD is the world's largest database of anonymised longitudinal primary care medical records.

The database has clinical and prescription data and can provide information to support pharmacovigilance (indication, utilisation, and risk/benefit profiles of drugs) and formal pharmacoepidemiologic studies, including information on demographics, medical symptoms, therapy (medicines, vaccines, devices), and treatment outcomes.

add to favorites email to friend print save as pdf

Related Stories

Breast cancer type linked to paternal cancer

Nov 28, 2011

The risk of breast cancer is increased by genetic and lifestyle factors such as the inherited BRCA2 gene, age of having first child, or use of hormone replacement therapy (HRT). New research published in BioMed Central's ...

Heart disease beats breast cancer as the biggest killer

Jun 19, 2011

Breast cancer accounts for almost a third of all cancer cases reported in women. However advances in the treatment for breast cancer, and early detection, have improved the chances of survival from the disease. New research ...

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.